ibandronic acid has been researched along with Osteoporotic Fractures in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, D; Ke, L; Liu, J; Luo, F; Mori, T; Wan, Y; You, R; Yu, G; Zhang, Y | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
| McConnell, M; Shieh, A | 1 |
| Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A | 1 |
| Lee, DR; Lee, J | 1 |
| Adami, S; Gatti, D; Kunnathully, V; Orsolini, G; Rossini, M | 1 |
| Amling, M; Felsenberg, D; Hadji, P; Hofbauer, LC; Kandenwein, JA; Kurth, A | 1 |
| Barr, C; Day, BM; Felsenberg, D; Harris, S; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, J; Silverman, S | 1 |
| Agodoa, I; Kruse, M; Orwoll, E; Parthan, A; Silverman, S | 1 |
| Bolognese, MA; Bone, HG; Bonnick, S; Brown, JP; Dakin, P; Ferreira, I; Hall, J; Ho, PR; Recknor, C; Roux, C; van den Bergh, JP; Wagman, RB | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Reid, IR | 1 |
| Asao, Y; Hagino, H; Hashimoto, J; Inoue, T; Ito, M; Katsumata, K; Mizunuma, H; Nakamura, T; Nakano, T; Shinomiya, K | 1 |
| Ju, JH; Jung, SM; Koh, JH; Kwok, SK; Lee, J; Myong, JP; Park, SH | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Cotté, FE; Fardellone, P; Gaudin, AF; Mercier, F; Roux, C | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Cooper, C; Hartl, F; Lewiecki, EM; Mehta, D; Papapoulos, SE; Thompson, E | 1 |
| Boyer, KM; Esses, SI; Finkelstein, J; Goldberg, MJ; Hitchcock, K; Jenkins, J; Keith, M; McGuire, R; Sluka, P; Turkelson, CM; Watters, WC; Wies, JL; Woodard, E | 1 |
| Cheung, WH; Chow, DH; Leung, AH; Leung, KS; Qin, L | 1 |
9 review(s) available for ibandronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2023 |
Osteoporosis treatment: why ibandronic acid?
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Osteoporotic Fractures | 2013 |
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; United States | 2014 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.
Topics: Aged; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risk Factors | 2010 |
2 trial(s) available for ibandronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Analgesics; Bone Density Conservation Agents; Diphosphonates; Drug Utilization; Female; Humans; Ibandronic Acid; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Motor Activity; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Treatment Outcome | 2014 |
Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures | 2015 |
10 other study(ies) available for ibandronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Cost-Benefit Analysis; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Teriparatide; Zoledronic Acid | 2021 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Republic of Korea; Retrospective Studies; Risedronic Acid | 2019 |
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Male; Markov Chains; Osteoporosis; Osteoporotic Fractures; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Femoral Fractures; Femur; Genu Valgum; Humans; Ibandronic Acid; Logistic Models; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2016 |
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Epidemiologic Methods; Female; France; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures | 2010 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
The treatment of symptomatic osteoporotic spinal compression fractures.
Topics: Bone Density Conservation Agents; Calcitonin; Combined Modality Therapy; Diphosphonates; Evidence-Based Medicine; Fractures, Compression; Humans; Ibandronic Acid; Nerve Block; Organometallic Compounds; Osteoporotic Fractures; Pain Measurement; Spinal Fractures; Thiophenes; Vertebroplasty | 2011 |
Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing.
Topics: Animals; Bone Remodeling; Bony Callus; Diphosphonates; Female; Femoral Fractures; Fracture Healing; Ibandronic Acid; Osteocalcin; Osteoclasts; Osteoporotic Fractures; Random Allocation; Rats; Rats, Sprague-Dawley; Vibration; X-Ray Microtomography | 2011 |